Quantum BioPharma anticipates funding to extend past March 2027.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Financial Position: Quantum BioPharma reported a stronger financial position at the end of Q3 2025, with reduced liabilities, increased shareholder equity, and ongoing efficiencies, alongside a robust product pipeline targeting brain disorders and alcohol health.
Unbuzzd Wellness Financing: Unbuzzd Wellness has initiated a Reg D financing for up to $5M to support a potential public transaction, which will allow Quantum to monetize its holdings without dilution.
Product License and MS Program: Health Canada granted a Product License for Qlarity, a natural health product, while Quantum's partnership with Massachusetts General Hospital is advancing in the MS program, with promising results from the Lucid-MS compound.
Cryptocurrency Strategy: Quantum continues to manage its treasury risk through cryptocurrency investments, reporting significant profits of $572,000, primarily from Bitcoin, and aims to maintain a strong financial position beyond March 2027.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like QNTM with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on QNTM
About QNTM
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quantum Biopharma Shareholders File Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP announces a class action lawsuit on behalf of Quantum Biopharma Ltd. shareholders, alleging securities fraud by the company and its executives, which could undermine investor confidence and further depress stock prices.
- Manipulative Trading Allegations: The complaint accuses financial institutions like CIBC and RBC of placing thousands of spoofed sell orders to create a false impression of declining stock prices, leading other investors to sell at artificially low prices and incurring significant losses.
- Investor Rights Protection: Shareholders must apply by February 23, 2026, to be appointed as Lead Plaintiff in the class action, highlighting their strong concerns regarding corporate governance and transparency.
- Law Firm Credentials: Pomerantz LLP, a leading firm in securities class litigation with over 85 years of experience, is dedicated to fighting for the rights of victims of securities fraud, having recovered millions in damages for class members historically.
Continue Reading
Quantum Biopharma Shareholders File Class Action Lawsuit
- Class Action Initiated: Pomerantz LLP announces a class action lawsuit on behalf of Quantum Biopharma Ltd. shareholders, alleging securities fraud by the company and its executives, which could undermine investor confidence and lead to further stock price declines.
- False Trading Allegations: The lawsuit claims that financial institutions like CIBC and RBC executed thousands of spoofed sell orders to create a false impression of Quantum's stock price decline, misleading other investors into selling their shares at artificially low prices, thereby harming investor interests.
- Investor Action Deadline: Affected Quantum shareholders must apply by February 23, 2026, to be appointed as Lead Plaintiff in the class action, highlighting the potential impact of this case on shareholder rights and its significance.
- Law Firm Background: Pomerantz LLP is a prominent securities class action law firm with over 85 years of experience, dedicated to fighting for the rights of victims of securities fraud, having recovered millions in damages for class members historically.
Continue Reading